Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli

Immunology

Volumn 123, Issue 4, 2008, Pages 600-605

  Kullberg, Bart Jan ^a   Ferwerda, Gerben ^a   De Jong, Dirk J ^a   Drenth, Joost P H ^a   Joosten, Leo A B ^a   Van Der Meer, Jos W M ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; NOD2; Toll like receptors; Tumour necrosis factor

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOKINE; LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CROHN DISEASE; CROSS TOLERANCE; DOWN REGULATION; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INCUBATION TIME; INTESTINE FLORA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

BACTERIA; CELLS, CULTURED; COLON; CROHN DISEASE; ENTEROCYTES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; INTESTINAL MUCOSA; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PEPTIDOGLYCAN; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39549120903     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02735.x     Document Type: Article

References (25)

1. Hugot J-P, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996 379 : 821 3.
2. Hugot J-P, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 411 : 599 603.
3. Hampe J, Grebe J, Nikolaus S et al. Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002 359 : 1661 5.
4. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 : 603 6.
5. Gutierrez O, Pipaon C, Inohara N et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J Biol Chem 2002 277 : 41701 5.
6. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003 278 : 8869 72.
7. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through Nod2. Implications for Crohn's disease. J Biol Chem 2003 278 : 5509 12.
8. Netea MG, Kullberg BJ, de Jong D et al. NOD2 mediates induction of the antiinflammatory signals induced by TLR2-ligands: implications for Crohn's disease. Eur J Immunol 2004 34 : 2052 9.
9. van Heel DA, Ghosh S, Hunt K et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005 365 : 1794 6.
10. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 53 : 1658 64.
11. Kobayashi KS, Chamaillard M, Ogura Y et al. NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005 307 : 731 4.
12. Maeda S, Hsu L-C, Liu H et al. NOD2 mutation in Crohn's disease potentiates NF-κB actvity and IL-1β processing. Science 2005 307 : 734 8.
13. Netea MG, Ferwerda G, de Jong DJ, Girardin SE, Kullberg BJ, van der Meer JW. NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-of-function phenotype. Neth J Med 2005 63 : 305 8.
14. Netea MG, Ferwerda G, De Jong DJ et al. NOD2 modulates specific Toll-like receptor pathways for the induction of cytokine release. J Immunol 2005 174 : 6518 23.
15. Sato S, Nomura F, Kawai T et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 2000 165 : 7096 101.
16. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 2001 166 : 5161 7.
17. Endres S, Cannon JG, Dempsey RA et al. In vitro production of IL-1β, IL-1α, TNF and IL-2 in healthy subjects: distribution, effect of oral cyclooxygenase inhibitors and evidence of independent gene regulation. Eur J Immunol 1989 19 : 2327 33.
18. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not Toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000 165 : 5780 7.
19. Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via toll-like receptor 2. J Med Microbiol 2004 53 : 735 40.
20. van Deventer SJ. Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999 13 (Suppl. 4 3 8.
21. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997 337 : 1029 35.
22. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998 161 : 3143 9.
23. Watanabe K, Kagaya K, Yamada T, Fukazawa Y. Mechanism for candidacidal activity in macrophages activated by recombinant gamma-interferon. Infect Immun 1991 59 : 521 8.
24. Marks DJ, Harbord MW, MacAllister R et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006 367 : 668 78.
25. Netea MG, Van der Meer JW, Sutmuller RP, Adema GJ, Kullberg BJ. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother 2005 49 : 3991 6.